Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

Bruno Paiva; Irene Manrique; Julie Rytlewski; Timothy Campbell; Christian C. Kazanecki; Nathan Martin; Larry D. Anderson; Jesús G. Berdeja; Sagar Lonial; Noopur S. Raje; Yi Lin; Philippe Moreau; Jesús F. San-Miguel; Nikhil C. Munshi; Shari M. Kaiser

doi:10.1158/2643-3230.BCD-23-0044

Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C. Kazanecki, Nathan Martin, Larry D. Anderson, Jesús G. Berdeja, Sagar Lonial, Noopur S. Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari M. Kaiser

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10^-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.

Original language	English (US)
Pages (from-to)	365-373
Number of pages	9
Journal	Blood cancer discovery
Volume	4
Issue number	5
DOIs	https://doi.org/10.1158/2643-3230.BCD-23-0044
State	Published - Sep 2023

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/2643-3230.BCD-23-0044

Cite this

Paiva, B., Manrique, I., Rytlewski, J., Campbell, T., Kazanecki, C. C., Martin, N., Anderson, L. D., Berdeja, J. G., Lonial, S., Raje, N. S., Lin, Y., Moreau, P., San-Miguel, J. F., Munshi, N. C., & Kaiser, S. M. (2023). Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. Blood cancer discovery, 4(5), 365-373. https://doi.org/10.1158/2643-3230.BCD-23-0044

Paiva, B, Manrique, I, Rytlewski, J, Campbell, T, Kazanecki, CC, Martin, N, Anderson, LD, Berdeja, JG, Lonial, S, Raje, NS, Lin, Y, Moreau, P, San-Miguel, JF, Munshi, NC & Kaiser, SM 2023, 'Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel', Blood cancer discovery, vol. 4, no. 5, pp. 365-373. https://doi.org/10.1158/2643-3230.BCD-23-0044

@article{24886e4dc6ce4ff9b68477d04103bff5,

title = "Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel",

abstract = "The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.",

author = "Bruno Paiva and Irene Manrique and Julie Rytlewski and Timothy Campbell and Kazanecki, {Christian C.} and Nathan Martin and Anderson, {Larry D.} and Berdeja, {Jes{\'u}s G.} and Sagar Lonial and Raje, {Noopur S.} and Yi Lin and Philippe Moreau and San-Miguel, {Jes{\'u}s F.} and Munshi, {Nikhil C.} and Kaiser, {Shari M.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

month = sep,

doi = "10.1158/2643-3230.BCD-23-0044",

language = "English (US)",

volume = "4",

pages = "365--373",

journal = "Blood cancer discovery",

issn = "2643-3230",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

AU - Paiva, Bruno

AU - Manrique, Irene

AU - Rytlewski, Julie

AU - Campbell, Timothy

AU - Kazanecki, Christian C.

AU - Martin, Nathan

AU - Anderson, Larry D.

AU - Berdeja, Jesús G.

AU - Lonial, Sagar

AU - Raje, Noopur S.

AU - Lin, Yi

AU - Moreau, Philippe

AU - San-Miguel, Jesús F.

AU - Munshi, Nikhil C.

AU - Kaiser, Shari M.

PY - 2023/9

Y1 - 2023/9

N2 - The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.

AB - The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.

UR - http://www.scopus.com/inward/record.url?scp=85169502244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169502244&partnerID=8YFLogxK

U2 - 10.1158/2643-3230.BCD-23-0044

DO - 10.1158/2643-3230.BCD-23-0044

M3 - Article

C2 - 37486974

AN - SCOPUS:85169502244

SN - 2643-3230

VL - 4

SP - 365

EP - 373

JO - Blood cancer discovery

JF - Blood cancer discovery

IS - 5

ER -

Time-Dependent Prognostic Valu of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this